FROM OUR EXPERTS
This question has not been answered by one of our experts yet.
Insulin nomenclature is clearly confusing. Among other reasons:
The same product may have several different names; the names may be different in the U.S. compared to other countries; the same product may be made by several manufacturers and given differing names.
The product may be from different sources (previously all insulin came from animal pancreases: beef, pork, or mixed beef/pork; but now-a-days, insulins usually are semisynthetic human).
Insulins are classified by duration of action, as being rapid, intermediate, and prolonged.
Several manufacturers may also mix two insulin products into the same vial, producing mixtures of 70% one and 30% another, or 50/50. To make it worse, what the US calls 70/30 would be called 30/70 in Europe! And in the US, 70/30, 75/25, and 50/50 are the usual mixtures, but in Europe there will be others such as 80/20 (oops, 20/80).
Some of the "big players" in the insulin arena are described below. I give the U.S. brand name first, then common na...
Generic Name: INSULIN LISPRO - INJECTION Pronounced: (IN-sue-lin LISS-pro) Humalog SubQ Uses
Insulin lispro is a man-made product almost identical to
human insulin that is used to treat diabetes mellitus. Like other insulin
products, it works by helping sugar (glucose) get into cells. It starts working
faster and lasts for a shorter time than regular insulin.
Insulin lispro is usually used in combination with a
medium- or long-acting insulin product injected under the skin to control high
blood sugar. In some diabetics, insulin lispro may be used alone or with oral
diabetes drugs (e.g., sulfonylureas like glyburide or
Even with diabetes, you can lead an active and healthy
life if you eat a balanced diet, exercise regularly, and take your insulin as
directed. Controlling high blood sugar helps prevent kidney damage, blindness,
nerve problems, loss of limbs, and sexual function problems. Proper control of
diabetes may ...
If you forgot to test, you’re in good company. It seems that the scientific researchers whom you rely on for your professional guidance on diabetes made the same mistake. When they tested the short-acting insulins, they forgot that the great majority of us with type 2 diabetes carry around too much weight. This awful report just came out in a late-breaking abstract presented at the American Diabetes Association’s scientific sessions in Chicago . Dr. Jean L. Ardilouze, a professor of medicine at University of Sherbrooke in Quebec, Canada, and three colleagues presented “In Obese Subjects with Type 2 Diabetes, Are Short Acting Insulin Analogues That Short?” Their conclusion was this: In healthy normal weight subjects, our results reproduced data accepted and used in daily practice for insulin prescriptions. However, in a population of obese subjects with type 2 diabetes, we show for the first time that plasma levels of short-acting insulins are blunted, at low dosage, and severely delay...
You should know
Answers to your question are meant to provide general health information but should not replace medical advice you receive from a doctor. No answers should be viewed as a diagnosis or recommended treatment for a condition. Content posted by community members does not necessarily reflect the views of Remedy Health Media, which also reserves the right to remove material deemed inappropriate.